Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Joint Authors
Lee, Christine
Louie, Thomas J.
Weiss, Karl
Gerson, Marvin
Arnott, Wendy
Gorbach, Sherwood L.
Valiquette, L.
Source
Canadian Journal of Infectious Diseases and Medical Microbiology
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-05-24
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials.
Methods.
Patients received fidaxomicin or vancomycin 1.
Patients were assessed for clinical response recurrence of infection and sustained clinical response for 28 days after treatment completion.
Patients at increased risk of recurrence were subjected to subgroup analyses.
Results.
Clinical response rates for fidaxomicin (90.0%) were noninferior to those with vancomycin (92.2%; 95% confidence interval for difference: −7.7, 3.5).
However, fidaxomicin-treated patients had lower recurrence (14.4% versus 28.0%, p = 0.001 ) and higher sustained clinical response (77.1% versus 66.3%, p = 0.016 ).
Compared with vancomycin, fidaxomicin was associated with lower recurrence rates in all subgroups, reaching statistical significance in patients with age ≥ 65 years (16.0% versus 30.9%, p = 0.026 ), concomitant antibiotic use (16.2% versus 38.7%, p = 0.036 ), and non-BI strains (11.8% versus 28.3%, p = 0.004 ).
Higher sustained clinical response rates were observed for fidaxomicin compared with vancomycin in all subgroups; this was statistically significant in the non-BI subgroup (82.8% versus 69.1%, p = 0.021 ).
Conclusions.
In Canadian patients, fidaxomicin was superior to vancomycin in sustaining clinical response and reducing CDI recurrence.
American Psychological Association (APA)
Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. 2016. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology،Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
Modern Language Association (MLA)
Lee, Christine…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology No. 2016 (2016), pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
American Medical Association (AMA)
Lee, Christine& Louie, Thomas J.& Weiss, Karl& Valiquette, L.& Gerson, Marvin& Arnott, Wendy…[et al.]. Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology. 2016. Vol. 2016, no. 2016, pp.1-8.
https://search.emarefa.net/detail/BIM-1100012
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1100012